Hedge Funds Bet Big on Merck: A New Favorite Dividend Stock Among Investors

In a notable shift within the high-stakes world of financial maneuvering, hedge funds have recently started to gravitate towards a particular dividend stock, offering both lucrative returns and undervalued stability. The markets have experienced slight upticks, with all major US stock indices showcasing robust performance in May 2024 despite ongoing concerns about high interest rates and predictions of an imminent market correction.

According to insights from top financial analysts, hedge funds have been shedding their US stock holdings significantly since the start of the year. This selloff has mainly been driven by persistent inflation concerns and the Federal Reserve's firm stance on maintaining elevated interest rates for a protracted period. Despite this trend, not all stocks are being cast aside. A standout in this scenario is Merck & Co (NYSE: MRK), a pharmaceutical giant that hedge funds have been accumulating aggressively.

As of May 26, 2024, an impressive tally of over 95 hedge funds have amassed shares in Merck & Co. worth approximately $8.11 billion. Leading the charge is Fisher Asset Management, with a formidable investment of $1.83 billion in this pharma heavyweight.

Merck & Co (NYSE: MRK), based in New Jersey, boasts a market cap of $327.97 billion and is renowned for its lineup of blockbuster cancer medications, particularly the PD-L1 inhibitor Keytruda. Keytruda's efficacy spans multiple cancer types, contributing to around 45% of Merck's drug sales. This diverse and robust pipeline likely makes Merck a favored pick among hedge funds.

The company's fiscal health is also drawing attention. Merck reported stronger-than-expected sales and earnings in the latest quarter, and its stock price rallied by 20.3% this year, outperforming the pharmaceutical industry's average gain of 15.3%. Furthermore, Merck's track record of consistent dividends over the past 40 years, paying out every quarter, strengthens its appeal among income-focused investors. Currently, Merck offers a trailing dividend yield of 2.40% and a forward yield of 2.51%, with a commendable annual dividend growth rate of 8.00% over the past five years.

For those considering alternatives to dividend stocks, the Ascent Income FundThe Ascent Income Fund by EquityMultiple could present an interesting option for those considering alternatives to dividend stocks. This fund is designed to provide stable income from senior commercial real estate debt positions, boasting a historical distribution yield of 12.1%. The focus on first-mortgage loans ensures a priority in payments, which, alongside flexible liquidity options, makes it an attractive proposition for income-focused investors seeking diversification.

The Ascent Income Fund adheres to rigorous underwriting standards, evaluating each loan and borrower meticulously to mitigate risk. The portfolio spans various geographies and property sectors, enhancing economic diversification. This fund targets a maximum loan-to-value (LTV) ratio of 75% on a whole-loan basis, typically keeping first-liens below 65% LTV.

Investors in the Ascent Income Fund have the advantage of redemption options after one year, providing a level of liquidity rarely offered in real estate investments. Targeting net annualized returns of 11-13%, with quarterly distributions, this fund could be a valuable addition to any income-focused portfolio. First-time investors can even get started with a minimum investment of just $5,000.

While Merck & Co (NYSE: MRK) remains a strong candidate for dividend stock investment, exploring high-yield alternatives like the Ascent Income Fund by EquityMultiple can offer investors a well-rounded and resilient portfolio. By balancing dividend-paying stocks with alternative investments, traders can more confidently navigate market uncertainties and achieve diversified income streams.